Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 5;19(15):9648.
doi: 10.3390/ijerph19159648.

The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?

Rafaela Malinaric  1   2 , Guglielmo Mantica  1 , Lorenzo Lo Monaco  1   2 , Federico Mariano  1   2 , Rosario Leonardi  3 , Alchiede Simonato  4 , André Van der Merwe  5 , Carlo Terrone  1   2
Affiliations
Review

The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?

Rafaela Malinaric et al. Int J Environ Res Public Health. .

Abstract

The aim of this review is to analyze and describe the current landscape of bladder cancer diagnostic and surveillance biomarkers. We researched the literature from 2016 to November 2021 to find the most promising new molecules and divided them into seven different subgroups based on their function and location in the cell. Although cystoscopy and cytology are still the gold standard for diagnosis and surveillance when it comes to bladder cancer (BCa), their cost is quite a burden for national health systems worldwide. Currently, the research is focused on finding a biomarker that has high negative predictive value (NPV) and can exclude with a certainty the presence of the tumor, considering missing it could be disastrous for the patient. Every subgroup has its own advantages and disadvantages; for example, protein biomarkers cost less than genomic ones, but on the other hand, they seem to be less precise. We tried to simplify this complicated topic as much as possible in order to make it comprehensible to doctors and urologists that are not as familiar with it, as well as encourage them to actively participate in ongoing research.

Keywords: biomarkers; bladder cancer; diagnosis; surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
See this image and copyright information in PMC

References

    1. Aronson J.K., Ferner R.E. Biomarkers—A General Review. Curr. Protoc. Pharmacol. 2017;76:9.23.1–9.23.17. doi: 10.1002/cpph.19. - DOI - PubMed
    1. Califf R.M. Biomarker definitions and their applications. Exp. Biol. Med. 2018;243:213–221. doi: 10.1177/1535370217750088. - DOI - PMC - PubMed
    1. Babjuk M., Burger M., Capoun O., Cohen D., Comperat E.M., Dominguez Escrig J.L., Gontero P., Liedberg F., Masson-Lecomte A., Mostafid A.H., et al. EAU Guidelines Office; Arnhem, The Netherlands: [(accessed on 30 November 2021)]. EAU Guidelines 2021 on NMIBC (Oppure MIBC). Edn. Presented at the EAU Annual Congress Milan 2021. Available online: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
    1. Cambier S., Sylvester R.J., Collette L., Gontero P., Brausi M.A., van Andel G., Kirkels W.J., Calais Da Silva F., Oosterlinck W., Prescott S., et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guerin. Eur. Urol. 2016;69:60–69. doi: 10.1016/j.eururo.2015.06.045. - DOI - PubMed
    1. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., Witjes A.J., Bouffioux C., Denis L., Newling D.W.W., Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006;49:466–477. doi: 10.1016/j.eururo.2005.12.031. - DOI - PubMed

Substances